Please assess the completion status of the following clinical trial:

Trial Title: COVID-19 Vaccine Response in Sickle Cell Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of sickle cell disease (HbSS, HbSC, HbSB0 thalassemia, HbSB+ thalassemia, HbS/Other)~2. Has not received any COVID-19 vaccination prior to enrollment~3. Scheduled for a COVID-19 vaccination (type does not matter) as part of routine clinical care~4. Willing and able to sign consent~Exclusion Criteria:~1. Unwilling to have labs drawn or complete study requirements.~2. Previous therapy curative of SCD (including bone marrow transplant and gene therapy)~3. Previous receipt of anti-COVID-19 antibody therapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Observational Cohort (Type: None): Previously unvaccinated persons with sickle cell disease who are scheduled to receive their initial COVID-19 vaccine series.

Based on this trial design, predict the completion outcome and termination type (if applicable).